This inventor holds 1 USPTO granted patent. Top assignee: Miles Inc.. Active years: 1993.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1993
Title: The Innovations of Robert N. Schut
Introduction
Robert N. Schut is an accomplished inventor based in Orange, Connecticut. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target leukotriene pathways. His work has implications for treating various respiratory and circulatory diseases.
Latest Patents
One of Robert N. Schut's notable patents is for "Aryl alkenoic acid derivatives as leukotriene antagonists." This patent describes a series of aryl alkenoic acid derivatives and their physiologically acceptable salts, which serve as potent leukotriene antagonists. These compounds are particularly useful in the treatment of respiratory diseases such as asthma, as well as other circulatory conditions. The derivatives are characterized by a general formula that includes specific structural components designed to enhance their therapeutic efficacy.
Career Highlights
Robert N. Schut has been associated with Miles Inc., where he has contributed to various research initiatives aimed at developing innovative pharmaceutical solutions. His expertise in medicinal chemistry has positioned him as a key player in the field, allowing him to make impactful advancements in drug development.
Collaborations
Throughout his career, Robert has collaborated with notable colleagues, including Trevor S. Abram and Peter Norman. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and the advancement of research in their respective fields.
Conclusion
Robert N. Schut's contributions to the field of medicinal chemistry, particularly through his patent on leukotriene antagonists, highlight his innovative spirit and dedication to improving health outcomes. His work continues to influence the development of treatments for respiratory and circulatory diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile